BIO

Sutro Works Toward A Better Ovarian Cancer ADC

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By 

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters

Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters

 
• By 

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.

Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

 
• By 

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow

Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow

 
• By 

Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.


BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs

BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs

 
• By 

There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.

BIO: Upbeat Zevra Advances Promising Rare Disease Portfolio

BIO: Upbeat Zevra Advances Promising Rare Disease Portfolio

 
• By 

With the urea cycle disorder treatment Olpruva launched and the NPC therapy arimoclomol closing in on US approval, Zevra is one to watch in the rare disease space.

Financial Market At The Start Of An Upswing, For Companies With Focused Strategies

Financial Market At The Start Of An Upswing, For Companies With Focused Strategies

 
• By 

Investors, advisors and companies that have raised cash recently insist funding is available and IPOs are possible for drug developers that can clearly outline future clinical milestones.

Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration

Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration

 
• By 

The France-based mid-sized drugmaker has solidified its pipeline through several external pacts in the past few years and its dealmaking is showing no signs of slowing down.


BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More

BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More

 
• By 

Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry. 

BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More

BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More

 
• By 

Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry. 

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

 
• By 

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence.   

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

 
• By 

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's  long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence. 


BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More

BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More

 
• By 

Insights from Day Two of the BIO International Convention in San Diego include the evolving pros and cons of partnering, user fees potentially supporting the FDA's AI ambitions, and J&J's view on dealmaking in 2024.  

BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More

BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More

 
• By 

Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.

EY: Buyers Need To Fill Revenue Gaps But M&A Targets May Be Scarce

EY: Buyers Need To Fill Revenue Gaps But M&A Targets May Be Scarce

 
• By 

In its Beyond Borders 2024 report, coinciding with the start of the BIO meeting, EY analysts see declining revenues for big pharma, which could be addressed by M&A, if the right takeouts exist.

Dealmaking Gives Biotechs Needed Financial Relief, But Deal Terms Are Under Pressure

Dealmaking Gives Biotechs Needed Financial Relief, But Deal Terms Are Under Pressure

 
• By 

Biotechs are ready to partner or sell assets to raise cash while turmoil continues in the financial markets, but they are doing so at lower valuations, with IRA and FTC concerns putting further pressure on deal terms.


Biopharma Investors, Companies Learning To Adjust To Financial Market Realities

Biopharma Investors, Companies Learning To Adjust To Financial Market Realities

 
• By 

Raising money will be difficult for the foreseeable future, so every part of the ecosystem from start-ups to public companies to VC firms is figuring out how to survive until cash is easily accessible again.

Northern Ireland Offers Biotechs Gateway To Both UK And EU

Northern Ireland Offers Biotechs Gateway To Both UK And EU

 
• By 

Countries from all over the world were plying their wares as desirable biotech clusters at the recent BIO meeting in Boston and Northern Ireland made a strong case for its potential as a prime location for life sciences starts-ups.

Feeling The 'K-Bio' Partnering Fervor In Boston: PharmAbcine’s Story

Feeling The 'K-Bio' Partnering Fervor In Boston: PharmAbcine’s Story

 
• By 

With Korea accounting for the second-highest number of attendees after the US this year, the BIO International Convention was crowded with biopharma firms from the country looking for partnerships. PharmAbcine CEO Jin-San Yoo shared his experience of the event and provides updates on key R&D programs including a unique TIE2 agonist antibody.

The Dealmaking Landscape According to Sanofi

The Dealmaking Landscape According to Sanofi

 
• By 

Monika Vnuk, head of Sanofi’s business development, tells Scrip that the best candidates are still commanding very high prices and outside inflammation and immunology, the French drugmaker is on the look-out for clinical rather than very early-stage assets.